$160-190k
Bioelectronic medicine for chronic disease
Open for applications
Bioelectronic medicine for chronic disease
101-200 employees
Open for applications
$160-190k
101-200 employees
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Essential Tremor is the most prevalent movement disorder in the world, with up to 5% of the global population affected by it. And yet, there were previously only two treatments: ongoing prescription drugs, which have side effects of drowsiness and nausea; or invasive surgery, which is costly and has risk of serious side effects.
Cala have developed a pioneering non-invasive treatment, which uses electrical stimulation from wearable device (it looks like a simple wristwatch) that monitors personal tremor levels and adapts its treatment to suit each patient. It is a world-leader in its field, and has revolutionized treatment for the 7 to 10 million Americans suffering from Essential Tremor.
Funding is focussed on expanding patient access, as well research into how to use their technology to treat Parkinson’s disease and other ailments.
Steph
Company Specialist at Welcome to the Jungle
Nov 2021
$77m
LATE VC
May 2019
$50m
SERIES C
East San Mateo, San Mateo, CA
Kate Rosenbluth
(CSO & Board Director)Formerly a Consultant at Genentech, Scientist in Residence at Brainlab and Lecturer at Stanford.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job